This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Engstrom PF , Ryan LM , Falkson G , Haller DG
Phase-Ii Study of Aminothiadiazole in Advanced Squamous-Cell Carcinoma of the Esophagus
American Journal of Clinical Oncology-Cancer Clinical Trials. 1991 Feb;14(1) :33-35
AbstractTwenty-three patients with advanced inoperable squamous cell carcinoma of the esophagus were treated with aminothiadiazole (A-TD) 125 mg/m2 weekly plus allopurinol daily in a phase II cooperative group trial. No patients responded to treatment; 17 patients progressed, three showed stable disease, and three were unevaluable. There were no life-threatening hematologic or metabolic toxicities. The median survival from study entry was 5 months. A-TD is not active in advanced squamous cell carcinoma of the esophagus.
NotesEV479 AMER J CLIN ONCOL-CANC CLIN T